GSK Vaccine Sales Drop 4%, Stock Falls Over 5%
nashnova research
GSK's third-quarter vaccine sales fell 4% year-on-year, dragging London-listed shares down 5.3% in early trading; total revenue still rose 4% to £8.9 billion, but the market's vaccine worries overshadowed gains elsewhere.
Why are vaccine sales sliding?
The biggest drag is weakening demand for Shingrix — GSK's blockbuster shingles vaccine — in the Chinese market.
RSV vaccine Arexvy saw sales fall 22%; flu vaccines were hit by both rising U.S. competition and delivery delays.
This means → it is not one product stumbling — the entire vaccine line is under pressure, and that is what spooked investors.
Revenue is still growing — what is carrying it?
Quarterly revenue reached £8.9 billion, up 4% year-on-year, driven mainly by specialty medicines — particularly HIV treatments and oncology drugs.
Respiratory, immunology, and inflammation drugs grew 19%, the fastest-expanding segment.
In plain terms = vaccines are dragging, but prescription drugs picked up the slack and kept the top line positive.
How important are vaccines to GSK?
Vaccines accounted for 28% of GSK's full-year revenue of £32.6 billion last year — one of the group's core income pillars.
This means → vaccines are not a side business. Nearly a third of revenue depends on them, and a sustained decline would hit group profit hard.
What is management doing about it?
CEO Luke Miels is pushing aggressively into oncology — GSK acquired U.S. biotech Nuvalent this year for $10.6 billion, its largest-ever biotech deal.
The company is also running a cost-cutting programme targeting annual savings of £1.9 billion by 2029.
This reflects a deliberate hedge against slowing vaccine growth: build the oncology pipeline through M&A while protecting margins through cost cuts.
What will the market watch next?
Two key checkpoints ahead: whether vaccine sales can stabilise, and whether the oncology pipeline can deliver meaningful revenue replacement over the medium term.
In plain terms = the 5% share-price drop shows the market has not seen answers yet — how deep the vaccine hole goes, and whether oncology can fill it, will set GSK's valuation trajectory for the next several quarters.
市场有风险，内容仅供研究参考，不构成投资建议。